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ABSTRACT: Chronic pain and restricted knee motion is a significant problem following the total knee arthroplasty (TKA). The molecular
pathogenesis of pain post‐TKA is not known and no targeted therapeutic intervention is available. The aim of this study was to
investigate whether pro‐inflammatory mediators are elevated in revision knee patients, indicating an active, ongoing inflammatory
process that may contribute to pain. Twelve key markers (pro‐inflammatory cytokines granulocyte‐macrophage colony‐stimulating factor
[GM‐CSF], interleukin 5 [IL‐5], IL‐8 and IL‐10, chemokines CCL2, CCL3, CCL4, and CCL13, mediators of angiogenesis Flt‐1, vascular
endothelial growth factor, and cell migration vascular cell adhesion molecule 1 and intercellular adhesion molecule 1) were measured in
knee tissue and synovial fluid (SF) from primary TKA (n = 29) and revision patients (n = 32). Indications for surgery were osteoarthritis
(OA) for primary TKA, and component loosening (n = 11), stiffness (n = 11), laxity pattern (n = 8), or progression of OA in patella
resurfacing (n = 3) for revision surgery. Pain levels (WOMAC score) were higher in revision than primary patients (p ≤ 0.05). Time from
primary to revision ranged from 8 months to 30 years (median 10 years). All markers were elevated in revision TKA; there was no trend
toward decreasing levels with greater time from primary surgery for any marker studied in SF. Similar results were seen in knee tissue.
We found no differences comparing indications for revision surgery (p ≥ 0.05). The elevation of inflammatory mediators in painful post‐
TKA knees requiring revision suggests active, chronic inflammation. Characterization of upregulated markers provides rationale for
targeted therapy, even many years from the primary surgery. © 2019 The Authors. Journal of Orthopaedic Research® published by Wiley
Periodicals, Inc. on behalf of Orthopaedic Research Society. J Orthop Res
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Primary total knee arthroplasty (TKA) is one of the most
commonly undertaken elective orthopedic procedures,
with >98,000 performed in 2016 in the United Kingdom.1
While the majority of patients have a successful outcome,
with reduced pain and improved function,2 a significant
proportion (10–20%) develop problems including joint
stiffness, reduced range of knee motion and pain, which
can ultimately require revision surgery.3
Extensive work has been undertaken to identify
patient factors (e.g., male/female sex, co‐morbidities,
mental health, and preoperative patient expectations)4
and surgical factors (e.g., implant design and surgical
technique)5 that predict poor outcome following TKA.
Increasingly, however, the role of patient biology as a
potential driver of pain, stiffness and dissatisfaction is
being considered.6
A relationship between levels of pro‐inflammatory
mediators (interleukin 6 [IL‐6], IL‐8, CCL2, C‐reactive
protein [CRP]) and pain levels in osteoarthritis has
been well described.7,8 However, our understanding of
the role of these mediators in pain and stiffness
following TKA is more limited. Gandhi et al.9 studied
28 patients undergoing TKA and found that higher
preoperative levels of tumor necrosis factor α (TNF‐α),
matrix metallopeptidase 13, and IL‐6 in synovial fluid
(SF) were associated with reduced improvement in
pain scores 2 years following TKA. Conversely, Zietek
et al.10 measured TNF‐α levels in SF taken at time of
primary surgery, and showed that higher levels of
TNF‐α were positively correlated with improved pain
scores at 6 weeks post‐surgery. Ugraş et al.11 mea-
sured SF levels of IL‐6 and CRP 24 h postoperatively
(sampling through a drainage tube placed intra‐
operatively) and found that higher levels of IL‐6
were associated with slower recovery. These studies
demonstrate uncertainty currently surrounding the
role of pro‐inflammatory cytokines in pain generation
following TKA.
We and others have previously shown that the post‐
TKA joint is associated with the persistence of
myofibroblasts and extensive fibrotic remodeling.12,13
More recently, we have investigated the expression of
39 soluble inflammatory proteins in SF, fat pad (FP),
and synovial membrane (SM) from patients undergoing
either primary or revision surgery.14 There was
elevated expression of a significant number of these
markers in each anatomical location: n = 26/39 markers
in SF, n = 22/39 in infrapatellar FP and n = 10/39 in SM
in revision versus primary knees.
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The markers investigated in this study fulfilled
two inclusion criteria; (i) they had previously been
found significantly elevated in SF in revision TKR
patients14; and (ii) they are well characterized
as mediators of fibrosis, inflammation, and/or
pain.12,13,15 Specifically we were interested in pro‐
inflammatory and immune cell recruitment media-
tors, including the CCL family of chemokines. GM‐
CSF is produced by fibroblasts, promotes neutrophil
and macrophage proliferation and maturation, and
is upregulated immediately postoperatively in
serum following TKA.16 IL‐5 is a B‐cell activating
cytokine elevated in serum immediately following
total knee replacement surgery17 that drives fibrosis
via Th2 B cell development and myofibroblast
activation.18 IL‐8, a CXC chemokine involved in
recruitment of neutrophils,19 has a positive correla-
tion with IL‐1 expression, suggesting that fibro-
blasts exposed to IL‐1 in the surgical knee may be a
source of IL‐814. IL‐10 has been demonstrated to
drive lung fibrosis when overexpressed, and this
process is dependent on CCL2 signaling20 and is
elevated in serum following knee surgery.17 CCL2
levels correlate positively with patient’s pain levels
following primary TKA, suggesting a role for CCL2
in pain pathogenesis, and recruitment of monocytes
by knee fibroblasts in vitro is dependent on CCL2
signaling.14 CCL3 and CCL4 are elevated immedi-
ately following knee surgery17 and CCL13 is a key
mediator of immune cell recruitment in chronic
inflammation. Intercellular adhesion molecule 1
(ICAM‐1) is an adhesion molecule expressed by
macrophages and other leukocytes and vascular
cell adhesion molecule 1 (VCAM‐1) is expressed by
activated endothelium and facilitates trans‐migra-
tion of immune cells into tissues. Soluble vascular
endothelial growth factor (VEGF) and Flt‐1 are
regulators of vessel growth; VEGF directly stimu-
lates new vessel formation and growth of existing
vessels, signaling through Flt‐1.21
However it is not known whether the inflammatory
response post‐TKA is acute and resolving, or whether
this process is chronic. To test this we examined the
levels of key pro‐inflammatory mediators in SF and
tissue of patients undergoing revision surgery and
compared this to time elapsed from their primary TKA
procedure.
Results presented here suggest that key, active pro‐
inflammatory and matrix deposition markers are
elevated in patients undergoing revision surgery,
demonstrating the presence of active and ongoing
chronic inflammation. These findings provide rationale
for targeted biological therapy in knee pain and
stiffness, even several years after the primary surgery.
Furthermore, these key mediators could be molecular
targets in patients with unexplained knee pain
following TKR.
METHODS
Patient Recruitment and Ethics
This research has been conducted following
ethical approval through the Newcastle Biobank
(17/NE/0361).
Tissue Collection and Patient Stratification
All patients undergoing revision surgery for failed
primary TKA were included in the study over a
two‐year period with infection as the only exclusion
criterion. Level of evidence—III, retrospective cohort
study comparing disease and control populations. SF,
infrapatellar fat pad (FP), and synovial membrane (SM,
suprapatellar pouch) were collected from patients
undergoing either primary (n = 29) or revision (n = 33)
TKA at the Freeman Hospital, Newcastle upon Tyne
(Table 1). Patient reported outcome measures (Western
Ontario & McMaster Universities Osteoarthritis Index,
WOMAC scores) were recorded as routine practice in
the Freeman hospital joint registry at the time of
surgery. Revision TKA patients were stratified as those
with osteolysis and loose components (n = 11), clinical
diagnosis of fibrosis with loss of movement (n = 11),
primary laxity pattern with functional instability
(n = 8, see Supplementary Methods for details), and
progression of osteoarthritis (previous patellofemoral
resurfacing) (n = 3). The clinical definition of joint
fibrosis and method for exclusion of infection was as
previously described12,22 (Supplementary Methods).
Types of knee replacement in the revision cohort and
surgical technique are described in Supplementary
Methods. Histological analysis was performed on 9/33
patients (see Supplementary Methods).
Infrapatellar Fat Pad and Synovial Membrane
Tissue was stored at 4°C in tissue culture media
containing 10% fetal calf serum, 1% L‐glutamine,
100 units/ml penicillin, and 100 μg/ml streptomycin
before processing. Tissue was homogenized in radio-
immunoprecipitation assay buffer supplemented with
protease and phosphatase inhibitors using a bead
homogenizer (TissueLyserII; Qiagen, Germantown,
MD). Homogenized samples were normalized to 1mg/
ml total protein (protein concentration measured using
a BCA protein assay (Pierce) as per manufacturer’s
instructions) and stored at −80°C before analysis.
Multi‐Array Protein Assays
Not all patients had fluid and both tissue samples
collected at the time of surgery. SF (primary n = 21
patients, revision n = 24 patients), and tissue homo-
genates from infrapatellar FP (primary n = 28
patients, revision n = 32 patients) and SM (primary
n = 29 patients, revision n = 32 patients) were
assessed for expression of 12 protein markers using
human V‐Plex electrochemiluminescence detection
kits from Meso‐Scale Discovery as per manufacturer’s
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instructions. Analysis of results was performed using
the MSD Discovery Workbench analysis software.
Statistical Analysis
Differences in patient demographics were examined
using Mann–Whitney U (Graph Pad, Prism, San Diego,
CA, version 7). Time from primary TKA to revision was
modeled using marker levels, age, and body mass index
(BMI) using multiple linear regression (performed in R,
available at www.r‐project.org). Differences in marker
levels between primary and revision patients, and
between different revision groups were examined using
Mann–Whitney U. Data are presented as mean±
standard error of the mean (SEM). p< 0.05 were
regarded as significant.
RESULTS
Pain Level in Revision and Primary TKA Patients
There were no differences in age, BMI, and sex
between the primary and revision groups, and within
the revision group when comparing different indica-
tions for revision surgery (Table 1). At time of
surgery, patient reported pain scores (WOMAC) were
higher in revision than primary TKA patients (52 ± 7
vs. 30 ± 3, p = 0.001, Table 1). No differences in pain
scores within the revision group when comparing
different indications for revision surgery were
observed (p = 0.13).
Elevation of Key Pro‐Inflammatory Cytokines, Chemokines
and Mediators of Fibrosis Many Years After Primary
Surgery
In total 12 markers were selected, all of which were
increased in SF when comparing revision to primary
patients (at a significance threshold of p =< 0.01 level,
U test, Table 214). In addition to quantifying these
markers in SF, we also examined their levels in FP
(Supplementary Results, Table S3) and SM tissue
(Supplementary Results, Table S4). In FP tissue
n = 10/12 markers were significantly elevated in revi-
sion patients compared to primary and in SM n = 4/12
markers were significantly elevated compared with
primary.
We next asked whether the levels of markers found
to be elevated in post‐TKA knees correlated with time
from primary surgery. To do this we fitted a multiple
linear regression model while controlling for age
and BMI.
Inflammation, fibrosis, and pain are dependent on
immune cell recruitment and activation. We have
previously found infiltration of CD68 +monocytes into
fibrotic tissue.14 Therefore, we first examined GM‐CSF
(increased ~threefold in SF of revision versus primary
knees), IL‐5 (increased sixfold), IL‐8 (increased 39‐fold),
and IL‐10 (increased twofold). All four markers were
elevated even many years after surgery in SF, FP, and
SM (Fig. 1). Seven patients had GM‐CSF levels >10‐
fold higher than in primary TKA patients >10 years
after their initial surgery.
Elevation of IL‐6 and of tumor necrosis factor‐α
(TNF‐α) at time of surgery in SF has previously been
shown to predict worse pain improvement 2 years post‐
TKA.9 However, IL‐6 was not detected in SF in revision
or primary samples in this study. Although TNF‐α was
>3‐fold increased in SF (p ≤ 0.0001) and was detectable
in all SF samples, TNF‐α was not robustly detected in
FP (0/28 primary, 9/32 revision) or SM tissue (2/28
primary, 9/32 revision).
The relationship between IL‐10 and CCL2 in driving
chronic fibrosis20 led us to investigate the temporal
expression of CCL2 (increased 13‐fold in SF revision vs.
primary), and other CCL family members (CCL3, 4,
and 13, increased >5‐fold in SF). All four CCLs were
elevated in fluid and tissue even many years after
primary surgery (Fig. 2).
Having demonstrated chronic elevation of pro‐
inflammatory and immune cell recruitment mediators,
we asked whether cell adhesion/migration markers
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Table 1. Patient Demographics
Primary
(n = 29)
All
Revisions
(n = 33) p Value
Osteolysis,
Loose
Components
Primary
Laxity
Pattern
(n = 8)
Progression
of OA(PFJ
Replacement,
n = 3)
Clinical
Diagnosisof
Fibrosis
(n = 11)
Age
(years, mean, SEM)
66± 2 68± 2 0.76 70± 3.2 67± 5 69± 6 65± 4
Gender 17M:12 F 16M:17 F 0.88 5M:6 F 4M:4 F 3 F 7M:4 F
BMI (Mean, SEM) 33± 1 33± 1 0.97 34± 2 33± 2 30± 2 34± 2
Time from primary to
revision surgery
(years, mean, SEM)
– 10± 1 – 16± 3 6± 1 6± 3 8± 2
WOMAC pain scores
(Mean, SEM)
30± 3 52± 7 0.001 65± 5 49± 4 34± 7 38± 4
No difference was found comparing age, gender, or body mass index (BMI) in revision versus primary patients, or comparing groups
according to indication for revision (p => 0.05, U test). Pain was significantly higher in revision versus primary patients (p =< 0.001).
SEM, standard error of mean.
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(ICAM‐1, VCAM‐1) and proangiogenic mediators
(VEGF and Flt‐1) also remain elevated. ICAM‐1 was
upregulated twofold in SF and FP (p ≤ 0.05, Table 2).
Both VEGF and Flt‐1 are upregulated in revision SF
(fourfold and 16‐fold). Again, there was no reduction in
level of these four markers with greater time from
surgery in both fluid and tissue (Fig. 3).
No marker studied demonstrated a reduction in level
with greater time from surgery (Figs. 1–3, tested in a
linear regression model). This finding suggests a chronic
type‐2 inflammatory response in revision patients.
No Significant Differences in Inflammatory Markers
Between Different Revision Groups
As we had a heterogeneous group of revision patients who
were undergoing surgery for one of four different indica-
tions we examined possible differences in levels of
inflammatory markers between different revision groups.
We found no significant differences in any of the markers
studied in SF, FP, or SM tissue (p ≥ 0.05 for all tests;
example graphs are shown in Figure 4, data is presented
in Tables 2, S3 and S4 [Supplementary Results]).
DISCUSSION
Knee pain and stiffness is a devastating complication
following total knee replacement yet our understanding
of the biology of the painful TKA remains incomplete.6
Previous studies have tested the hypothesis that the
level of inflammation pre‐ or peri‐operatively is corre-
lated with clinical outcome and/or pain.10,11 Here, we
have studied a group of patients undergoing revision
surgery for all causes (having excluded infection). We
report that in patients undergoing revision surgery,
who have higher pain scores than primary TKA
patients, there is elevation of key inflammatory
mediators in SF and knee tissue. This is present
irrespective of time from primary surgery, with low r2
and p values in multiple linear regression for all
markers tested against time. These findings suggest
that targeted modulation of chronic inflammation may
offer therapeutic benefit in the treatment of pain
following TKA.
Stiffness and joint fibrosis is a significant problem
following TKA. We have previously shown that fibrotic,
dense collagenous scar tissue is found in all patients
undergoing aseptic revision surgery for failed primary
TKA.12 The fibrotic tissue is characterized by the
deposition of a dense, disorganized extracellular matrix
of collagen23 populated by myofibroblasts.12,13
Although all revision knees in this cohort have joint
fibrosis, presumably there are differences in the
anatomic location and amount of fibrotic tissue present.
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Figure 1. Elevated levels of pro‐inflammatory mediators granulocyte‐macrophage colony‐stimulating factor (GM‐CSF), interleukin 5
(IL‐5), and IL‐8 are maintained over time following primary total knee arthroplasty (TKA) in synovial fluid and tissue in patients with
joint fibrosis. No significant change in the levels of pro‐inflammatory mediators GM‐CSF, IL‐5, and IL‐8 was found over time from
primary TKA surgery in synovial fluid, fat pad, or synovial membrane tissue. The red line indicates the mean level in primary tissue for
comparison. The black line represents the mean and black long dashed lines the 95% confidence interval. A linear regression model was
used; r2 and p values are presented for each analysis [Color figure can be viewed at wileyonlinelibrary.com]
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We have not been able to determine whether fibrosis is
a result of an ongoing inflammatory state caused by a
failing primary TKA, or is normal scar tissue found
post‐TKA. Consequently differences in the molecular
biology of the stiff TKA must be further investigated
and dissected out from those seen in TKAs that have
failed for other reasons (e.g., loosening, component mal‐
position). Animal models of joint fibrosis have been
developed and may provide further mechanistic in-
sights into the disease pathogenesis.24 Histological
analysis in this study showed polyethylene wear
particles that could have a pathogenic role in driving
chronic inflammation.
Treatment of joint fibrosis is currently limited to
physical therapy. Patients resistant to nonoperative
treatment require arthroscopic or more invasive sur-
gical procedures to excise and remove the soft tissue
contractures.25 The outcomes of surgically treated
posttraumatic fibrosis of the knee are poor, with most
patients unable to return to pre‐injury level of
function.26,27 Our understanding of the molecular
pathogenesis of joint fibrosis is incomplete and conse-
quently no targeted therapy is available. IL‐1 receptor
is expressed in high levels on the surface of knee
fibroblasts,15 and one pilot case series reported im-
proved range of motion following intra‐articular injec-
tion of Anakinra, an IL‐1 receptor antagonist,28
demonstrating the potential for targeted therapy.
Development of fibrosis and consequently knee stiff-
ness, manifest as restricted range of motion (ROM), is
associated with increased pain postoperatively,29 sug-
gesting that chronic inflammation may be a common
pathway for development of pain and restricted ROM
due to excessive scarring.
Suppressing the inflammatory response peri‐opera-
tively has been investigated in a randomized trial of
TKA patients.30 Administration of three doses of
intravenous hydrocortisone decreased systemic inflam-
mation (measured by serum IL‐6 levels) 24 h post-
operatively. Patients receiving steroid had improved
ROM at time of discharge, and although no long‐term
follow‐up data is available, dampening inflammation
may provide a potential clinical benefit.
Previous studies have measured pre‐ or peri‐opera-
tive levels of TNF‐α 9,10 and IL‐6.9,11 We found TNF‐α
threefold higher in revision versus primary SF, sup-
porting a possible role in promoting pain and inflam-
mation. However, IL‐6 was not upregulated in revision
knees suggesting that IL‐6 is most useful as an early
pre‐/peri‐operative biomarker.
In this cohort pain scores were higher in failed TKA
patients than patients undergoing primary surgery for
osteoarthritis. This demonstrates the challenges faced
to achieve a satisfactory outcome following revision,
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Figure 2. Elevated levels of Immune cell recruitment mediators CCL2, CCL3, and CCL4 in synovial fluid and tissue following primary
total knee arthroplasty (TKA) in patients with joint fibrosis. No significant change in the levels of CCL2, CCL3, and CCL4 was found over
time from primary TKA surgery in synovial fluid, fat pad, or synovial membrane tissue. The red line indicates the mean level in primary
tissue for comparison. The black line represents the mean and black long dashed lines the 95% confidence interval. A linear regression
model was used; r2 and p values are presented for each analysis [Color figure can be viewed at wileyonlinelibrary.com]
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and is consistent with previously reported higher levels
of chronic pain after revision TKA compared with
following primary TKA.31
Several limitations to the present study should be
noted. Revision patients studied here were a hetero-
geneous group undergoing surgery for all causes. We
have not been able to robustly identify differences in
the molecular profile comparing different indications
for revision. There is no previously published data on
differences in inflammatory microenvironment of the
post‐TKA knee to allow a power calculation to be
performed. Revision surgery is relatively infrequently
required following TKA, and despite an unbiased
patient selection strategy for our revision cohort to
maximize the number of patients recruited to the study,
with the only rule‐out clinical condition being infection,
we are likely to be underpowered to detect differences
between different indications for revision surgery in
this exploratory experimental study. We have compared
revision patients to primary patients with advanced
osteoarthritis; the ideal control group would be TKA
patients with a well‐functioning prosthesis and this
will be tackled in future studies. Biomarker changes
may be age‐related, and although we controlled for age
in multiple linear regression analysis we cannot
exclude an effect of age in revision patients,
particularly elderly patients who underwent primary
surgery >20 years ago. We were unable to control for
different analgesic regimens between patients, which
could influence outcomes and were not able to differ-
entiate neuropathic pain, which may have a different
pathogenesis and is known to occur in a sub‐set of TKA
patients.32
Data presented in this report suggest that the levels
of key biologically active pro‐inflammatory mediators
are locally elevated at time of revision surgery many
years after the initial procedure in failed TKAs. The
painful,14 fibrotic12 post‐TKA joint acquires a state of
unresolved inflammation with a signature resembling
that of a chronic allergic reaction.33 Markers with this
temporal regulation include those involved in matrix
formation (VEGF, Flt‐1) and the inflammatory cyto-
kines GM‐CSF, IL‐5 and IL‐8, and cell recruitment
chemokines CCL2, CCL3 and CCL4. Similar results
were obtained in tissue and SF. This finding has
implications when considering therapeutic interven-
tion. The elevation of these markers indicates an active
disease process, thus offering the possibility to inter-
rupt activated molecular pathways. Far from being
quiescent, the knee exists in state of chronic inflamma-
tion. In addition to reduced ROM knee fibrosis is a
painful condition.29,34 CCL2 correlates positively with
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Figure 3. Elevated levels of vascular endothelial growth factor (VEGF), vascular cell adhesion molecule 1 (VCAM‐1), and Intercellular
adhesion molecule 1 (ICAM‐1) in synovial fluid and tissue following primary total knee arthroplasty (TKA) in patients with joint fibrosis.
No significant change in the levels of VEGF, VCAM‐1, and ICAM‐1 was found over time from primary TKA surgery in synovial fluid, fat
pad, or synovial membrane tissue. The red line indicates the mean level in primary tissue for comparison. The black line represents the
mean and black long dashed lines the 95% confidence interval. A linear regression model was used; r2 and p values are presented for each
analysis [Color figure can be viewed at wileyonlinelibrary.com]
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pain levels14; blocking CCL2 signaling could reduce
pain symptoms in these patients.
Although we report elevation of inflammatory med-
iators in revision patients many years from primary
surgery, the question remains as to whether these
mediators are important in pathogenesis of TKA failure.
Longitudinal sampling is required to determine the
contribution of these mediators to the pathogenesis of
disease (e.g., fibrosis) that led to requirement of revision
surgery. In addition, these mediators may be important
in the 10–20% of patients that report unexplained knee
pain and dissatisfaction following TKA.35 A longitudinal,
prospective study is required to determine whether
chronic inflammation is present in patients with
unexplained pain not requiring revision surgery.
A number of biologically active markers involved in
inflammation and matrix deposition were significantly
elevated many years following primary TKA. Approved
therapeutics are available that target these molecules,
for example, CCL2, IL‐8, and CCL3, and further
studies are required to evaluate these compounds in
patients with stiff, painful failed TKAs. In addition,
prospective examination of the painful, stiff TKR is now
required to determine (i) whether chronic inflammation
is present in patients without a specific cause for their
pain, and (ii) to identify molecular mediators to direct
targeted immunomodulatory adjunctive therapy.
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